Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy

Atherosclerosis

Volumn 145, Issue 2, 1999, Pages 333-340

  Yoshimoto, Takanobu ^a   Naruse, Mitsuhide ^a   Shizume, Hiroshi ^a   Naruse, Kiyoko ^a   Tanabe, Akiyo ^a   Tanaka, Masami ^a   Tago, Katsuya ^a   Irie, Kaoru ^a   Muraki, Takamura ^a   Demura, Hiroshi ^a   Zardi, Luciano ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Fibronectin; Hypertension; Morphometry; Neointima formation; Pioglitazone; Thiazolidine; Vascular smooth muscle cell

Indexed keywords

BROXURIDINE; FIBRONECTIN; PIOGLITAZONE; THIAZOLIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CAROTID ARTERY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; ESSENTIAL HYPERTENSION; MALE; MORPHOMETRICS; MUSCLE HYPERTROPHY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, ABDOMINAL; ARTERIOSCLEROSIS; BROMODEOXYURIDINE; CAROTID ARTERIES; CELL DIVISION; DNA; FIBRONECTINS; HYPERTENSION; HYPERTROPHY; HYPOGLYCEMIC AGENTS; MALE; MESENTERIC ARTERIES; MUSCLE, SMOOTH, VASCULAR; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; THIAZOLES; THIAZOLIDINEDIONES; TUNICA INTIMA;

EID: 0032794799     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00085-4     Document Type: Article

References (39)

1. Ikeda H, Taketomi S, Sugiyamam Y, Shimura Y, Sohda T, Meguro K, Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim-Forsch 1990;40:156-62.
2. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Engl J Med 1994;331:1188-93.
3. Sowers JR, Standley PR, Ram JL, Jacober S. Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens 1993;6(Suppl.):260S-270.
4. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, Imaki T, Demura R, Aikawa E, Demura H. Antihypertensive and vasculo- and renoprotectie effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997;272:E989-96.
5. Shinohara E, Kihara S, Ouchi N, Funahashi T, Nakamura T, Yamashita S, Kameda-Takemura K, Matsuzawa Y. Troglitazone suppresses intimal formation following balloon in insulin-resistant Zucker fatty rats. Atherosclerosis 1998;136:275-9.
6. Igarashi M, Takeda Y, Ishibashi N, Takahashi K, Mori S, Tominaga M, Saito Y. Pioglitazone reduces smooth muscle cell density of rat carotid artery intima induced by balloon catheterization. Hormone Metab Res 1997;29:444-9.
7. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993;265:R726-32.
8. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-905.
9. Peuler JD, Phare SM, Iannucci AR, Hodorek MJ. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens 1996;9:188-92.
10. Morikang E, Benson SC, Kurtz TW, Pershadsingh HA. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens 1997;10:440-6.
11. Nabika T, Nara Y, Ikeda K, Endo J, Yamori Y. Genetic heterogeneity of the spontaneously hypertensive rats between the different sources. Hypertension 1991;18:12-6.
12. Fishman JA, Ryan GB, Karnovsky MJ. Endothelial regeneration in the rat carotid artery and the significance of endothelial denudation in the pathogenesis of myointimal thickening. Lab Invest 1975;32:339-51.
13. Rasband WS, Bright DS. NIH Image: a public domain image processing program for the Macintosh. Microbeam Anal Soc J 1995;4:137-49.
14. Mulvany MJ, Hansen PK, Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res 1978;43:854-64.
15. Owens GK, Schwartz SE, McCanna M. Evaluation of medial hypertrophy in resistance vessels of spontaneously hypertensive rats. Hypertension 1988;11:198-207.
16. Glukhova MA, Frid MG, Shekhonin BV, Vasilevskaya TD, Grunwald J, Saginati M, Koteliansky VE. Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent. J Cell Biol 1989;109:357-66.
17. Carnemolla B, Borsi L, Zardi L, Owens RJ, Baralle FE. Localization of the cellular-fibronectin-specific epitope recognized by the monoclonal antibody IST-9 using fusion proteins expressed in E. Coli. FEBS Lett 1987;215:269-73.
18. Borsi L, Carnemolla B, Castellani P, Rosellini C, Vecchio D, Allemanni G, Chang SE, Taylor-Papadimitriou J, Pande H, Zardi L. Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol 1987;104:595-600.
19. Ravalli S, Szabolcs M, Albala A, Michler RE, Cannon PJ. Increased immunoreactive endothelin-1 in human transplant coronary artery disease. Circulation 1996;94:2096-102.
20. Akyrek LM, Fellstrom BC, Yan ZQ, Hansson GK, Funa K, Larsson E. Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts. Am J Pathol 1996;149:1981-90.
21. Schwartz SM, Campbell GR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res 1986;58:427-44.
22. Thyberg J, Nilsson J, Palmberg L, Sjolund M. Adult human arterial smooth muscle cells in primary culture. Modulation from contractile to synthetic phenotype. Cell Tissue Res 1985;239:69-74.
23. Contard F, Sabri A, Glukhova M, Sartore S, Marotte F, Pomies JP, Schiavi P, Guez D, Samuel JL, Rappaport L. Arterial smooth muscle cell phenotype in stroke-prone spontaneously hypertensive rats. Hypertension 1993;22:665-76.
24. Kanzaki T, Shiina R, Saito Y, Zardi L, Morisaki N. Transforming growth factor-b receptor and fibronectin expressions in aortic smooth muscle cells in diabetic rats. Diabetologia 1997;40:383-91.
25. Owens GK, Schwartz SM. Alteration in vascular smooth muscle mass in the spontaneously hypertensive rat: role of cellular hypertrophy, hyperploidy, and hyperplasia. Circ Res 1982;51:280-9.
26. Olivetti G, Melissari M, Marchetti G, Anversa P. Quantitative structural changes of the rat thoratic aorta in early spontaneously hypertension. Circ Res 1982;51:19-26.
27. Mulvany MJ, Baandrup U, Gunderson HJG. Evidence for hyperplasia in mesenteric resistance vessels of spontaneously hypertensive rats using a 3-dimensional dissector. Circ Res 1985;57:794-800.
28. Kawaguchi M, Tanigawa K, Kato Y. A study of effect of CS-045, a new antidiabetic drug, on hypertension in spontaneously hypertensive rats. Endocr J 1995;42:557-61.
29. Uchida A, Nakata T, Hatta T, Kiyama M, Kawa T, Morimoto S, Miki S, Moriguchi J, Nakamura K, Fujita H, Itoh H, Sasaki S, Takeda K, Nakagawa M. Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR. Life Sci 1997;61:455-64.
30. Verma S, Bhanot S, Arikawa E, Yao L, McNeill JH. Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats. Pharmacology 1998;56:7-16.
31. Yamori Y, Ohta K, Ohtake M, Nara Y, Horie R, Ooshima A. Glucose metabolism in spontaneously hypertensive rats. Jpn Heart J 1978;19:559-60.
32. Mondon CE, Reaven GM. Evidence of abnormalities of insulin metabolism in rats with spontaneous hypertension. Metabolism 1988;37:303-5.
33. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneim-Forsch Drug Res 1997;47:29-35.
34. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M, Komoda T. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 1997;235:113-6.
35. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in athrogenesis. Free Radic Biol Med 1996;20:707-27.
36. Lehman JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995;270:12953-6.
37. Iijima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M, Sugimoto N, Liang YQ, Sudoh N, Toba K, Ouchi Y. Expression of proliferator-activated receptor γ (PPAR γ) in rat aortic smooth muscle cells. Biochem Biophys Res Commun 1998;247:353-6.
38. Graf K, Xi XP, Hsueh WA, Law RE. Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett 1997;400:119-21.
39. Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension 1998;31:152-61.